G2Gbio

지투지바이오 · 456160

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$643.8M (₩888.5B)

Overview

G2Gbio is a South Korean biotech company listed on KOSDAQ, Korea's tech-focused small-cap exchange, that works in the development of pharmaceutical and biological products.

Its products are aimed at medical and health-care end users. The filing's business description section contains only a table-of-contents entry and does not disclose specific products, services, or structural details, so no further factual characterisation can be confirmed from the available text.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$306.6K

▼ −45.0% YoY

Operating profit · FY2025

−US$8.8M

Loss widened

Net income · FY2025

−US$8.8M

Loss narrowed

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2024	FY2025
Revenue	US$557.2K(₩768.9M)	US$306.6K(₩423.1M)
Operating profit	−US$7.8M(−₩10.8B)	−US$8.8M(−₩12.2B)
Net income	−US$60.3M(−₩83.3B)	−US$8.8M(−₩12.1B)

Revenue

FY2024US$557.2K
FY2025US$306.6K

Operating profit

FY2024−US$7.8M
FY2025−US$8.8M

Net income

FY2024−US$60.3M
FY2025−US$8.8M

Key ratios (FY2025)

ROE

-20.7%

Debt/Eq

16.1%

Op. margin

-2884.2%

Net margin

-2857.1%

Rev. YoY

▼ −45.0%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?